ACC
AHA
AHA- New market research showcases need for re-training health care workforce on...Highlights: About half of health care providers surveyed said they haven’t had re-training in blood pressure measurement after leaving professional school. Nearly half of U.S. adults have high blood pressure, making accurate blood pressure ...
- New structural heart disease initiative aims to extend and improve patients...Embargoed for release November 17, 2019 2:30 p.m. ET PHILADELPHIA, November 17, 2019 — Millions of people are living with structural heart disease in the United States, and many may be unaware or lack effective diagnoses and treatments. It ...
- American Heart Association’s Chairman’s Award goes to Portland internis...The American Heart Association, a global force for longer, healthier lives, has bestowed its 2019 Chairman’s Award to Cheryl Pegus, M.D., M.P.H., president of Consumer Health Solutions and chief medical officer of Cambia Health Solutions in Portland, Oregon. ...
- General election 2019: PM puts corporation cuts on hold to help fund NHSBoris Johnson says plans to cut corporation tax to 17% next year are to be put on hold. ...
- Why more people are talking about the issue of social careSocial care pledges will be under intense scrutiny during the election, but why is it so important? ...
- NHS staff shortages put ‘cancer survival rates at risk’A Holyrood committee finds 18% of cancer patients in June were not seen within the six-week target. ...
- Potential Mechanisms of Sodium-Glucose Co-Transporter 2 Inhibitor-Related C...The findings of recent clinical trials have shown that sodium-glucose co-transporter 2 (SGLT2) inhibitors produce effects beyond glucose lowering and have demonstrated beneficial cardiovascular effects that have been observed across a broad range of patients with type 2 diabetes mellitus. ...
- Promise, Innovation, Potency, and Efficacy: The PIPE Dream of Sodium-Glucos...Arguably, no class of medications, specifically for patients with type 2 diabetes mellitus, has garnered as much excitement as the sodium-glucose co-transporter 2 (SGLT2) inhibitors. Type 2 diabetes mellitus is a highly prevalent and growing global problem, and patients with ...
- Renal Effects of Sodium-Glucose Co-Transporter InhibitorsSodium-glucose co-transporter 2 (SGLT2) inhibitors immediately reduce the glomerular filtration rate (GFR) in patients with type 2 diabetes mellitus. When given chronically, they confer benefit by markedly slowing the rate at which chronic kidney disease progresses and are the first ...
